



Symic Bio to Present at Upcoming October Conferences

SAN FRANCISCO, Oct. 2, 2017 – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Rinko Ghosh, President and Chief Business Officer, will present at the following conferences in October.

BioJapan 2017 Conference

Date: Thursday, Oct. 12, 2017
Time: 4:30 p.m. JST
Location: Pacific Convention Plaza Yokohama, Yokohama, Japan

2017 BIO Investor Forum

Date: Tuesday, Oct. 17, 2017
Time: 11 a.m. PDT
Location: Westin St. Francis Hotel, San Francisco

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vascular disease, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com